Similarly, the ADA advocates for individualized treatment goals and strategies tailored to address cardiovascular risk factors, suggesting the consideration of agents like SGLT2 inhibitors for patients with T2DM and high cardiovascular risk. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.